<DOC>
	<DOCNO>NCT01346982</DOCNO>
	<brief_summary>This clinical trial characterize drug interaction silimarine protease inhibitor darunavir/ritonavir .</brief_summary>
	<brief_title>Drug Interactions Between Silimarine Darunavir/Ritonavir</brief_title>
	<detailed_description>The silimarine main component milk thistle ( Sylibum marianum ) , medicinal herb , due attribute hepatoprotective property , widely use HIV infect patient 15 patient stable antiretroviral therapy include darunavir/ritonavir 600/100 mg twice day four week enrol . After inclusion study , patient receive treatment silimarine ( 150 mg every 8 hour ) day 1 two week later ( day 14 ) . On day 0 14 , blood sample draw immediately 1 , 2 , 4 , 6 , 8 , 10 12 hour administration darunavir/ritonavir , darunavir ritonavir concentration plasma determine high performance liquid chromatography use validated method .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patients receive antiretroviral therapy contain darunavir / ritonavir approve dose 600/100 mg twice daily least 4 week HIV viral load plasma &lt; 50 copy / mL Absence acute infection / tumor three month prior inclusion . Subject able follow treatment period , without suspicion poor adherence previous antiretroviral treatment . Any clinical historical observation could interfere pharmacokinetics medication , gastrointestinal illness surgery ( except herniotomy appendectomy ) , change composition plasma protein , indication hepatic renal dysfunction . Active alcohol consumption ( &gt; 50 g / day ) illicit drug ( except cannabis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Darunavir</keyword>
	<keyword>Silimarine</keyword>
	<keyword>interaction</keyword>
</DOC>